A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Phase 3 Completed 193 enrolled Kwang Dong Pharmaceutical co., ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).

Timeline

Start: 2021-05-10
Primary completion: 2023-05-16
Completion: 2023-05-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bremelanotide	Peptide	1.75 mg	Subcutaneous

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Summary

Timeline

Drugs

Indications